Senaste nyheterna

5 Januari 2023 13:00

Positive Top-line Clinical Data for Izokibep in Hidradenitis Suppurativa

Solna, Sweden, January 5, 2023. Affibody’s partner ACELYRIN, Inc. today announced top-line 12-week open label data from a Phase 2b/3 trial of izokibep in patients with moderate-to-severe Hidradenitis Suppurativa (HS).

4 Januari 2023 08:00

First HER2-low patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, January 4, 2023. Affibody AB (“Affibody”) today announced that the first patients have been dosed in a Phase 2 clinical basket study of the PET imaging agent 68Ga-ABY-025 PET for non-invasive quantification of HER2-status in solid tumors. ABY-025 is based on an Affibody® molecule that binds strongly to HER2 – a cell surface protein implicated in several forms of cancer. The high aff

23 December 2022 08:00

Affibody signs €20 million loan agreement with the EIB to finance the development of next generation’s biopharmaceuticals against cancer and inflammatory diseases

Affibody signs €20 million loan agreement with the EIB to finance the development of next generation’s biopharmaceuticals against cancer and inflammatory diseases
Solna, Sweden, December 23, 2022. Affibody Medical AB (“Affibody”) today announced that the European Investment Bank, EIB, backed by the InvestEU programme, has provided a €20 million venture debt loan facility to Affibody. The inves

8 November 2022 16:00

Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022

Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022. • Izokibep Phase 2 PsA Oral presentation to take place on November 13, 2022, in a session at 3:00PM-4:30PM (EST) / 21:00-22:30 (CET).

7 November 2022 15:15

Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116

Solna, Sweden, November 7, 2022. Affibody’s licensee Rallybio Corporation, has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. • A single 100 mg subcutaneous dose demonstrated a reduction of >99% in free C5 and was generally well-tolerated. • Phase 1 Multiple Ascending Dose (MAD) study expected to commence in Q1, 2023

3 Juni 2022 11:15

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

• Data suggest efficacy over standard of care for the treatment of psoriatic arthritis
• Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class
• Supports hypothesis that izokibep offers greater efficacy with high potency and small size, as well as strategy of evaluating IL-17A inhibition’s potential for transforma

19 Maj 2022 14:50

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 19, 2022 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted.
Adoption of the income statement and the balance sheet; allocation of result
The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with submitted accounting documents. The Annual General Mee

Kontakter

David Bejker

Presskontakt CEO